In drug research, structures to which drugs are directed or bind to are called targets.
Detailed description
Targets are often molecules that are essential for the development or persistence of a disease. In the development of a new drug, a potential target is searched first. Drugs should bind to that target and influence it, for example by switching it on or off.
The INCubator for Antibacterial Therapies in Europe, INCATE, aims to support innovators in the early stages of developing therapies in the field of antimicrobial resistance. The German Center for
Please use this graphic only in connection to this press release.
Colistin is a last-line reserve antibiotic for the treatment of infections caused by extremely multidrug-resistant (XDR) Gram-negative bacteria. The recent emergence and global spread of the mobile
Scanning electron micrograph: C. difficile cells were provided by Nicole Metzendorf from the Department of Microbial Physiology and Molecular Biology, Institute of Microbiology, and imaged by Rabea Schlüter, Imaging Center of the Department of Biology, University of Greifswald, Germany.
Please use this image only in connection with this press release.
Infections with the bacterium Clostridioides difficile (C. difficile for short) frequently recur due to permanent stages remaining in the intestine. A drug that also effectively combats the permanent
The pathogen Helicobacter pylori, which is responsible for highly prevalent diseases such as gastric ulcers or cancer, has a weak spot that could be used to produce new drugs. This was discovered by a
In many infections, even proper antibiotic treatment does not lead to the expected therapeutic success. In the case of treatment with antibiotics, the doctor usually first decides which antibiotic to prescribe based on the type of infection. If resistance to the antibiotic already prescribed is ...
Alongside preventive strategies such as vaccines, small molecule drugs (SMDs) are an essential pillar in combating infectious diseases. SMDs are chemically defined compounds that interact with
Diagnostics is often the first and critical step in the treatment of virological and bacterial infectious diseases. It allows identification of the pathogen, assessment of the severity of the disease
Current developments in infection research challenge the scientific community: Many problems can only be solved if expertise from different disciplines comes together. To meet this challenge, the DZIF
EBViously, a spin-off from Helmholtz Munich (HMGU), is led by world-leading experts in Epstein-Barr virus biology, genetics, and immunity and was founded to develop a safe and highly effective
